AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00662519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neulasta (Pegylated)
Description: Subjects will receive 6mg/dose given every 2 weeks for 12 weeks. Subjects less than 45kg will receive 100mcg/kg/dose every 2 weeks for 12 weeks.
Study NCT04561375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: 30 µg tablet of sublingual sufentanil
Study NCT04561375 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: 50 µg fentanyl
Study NCT03216018 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention program: In Favor of Resilient Self
Description: Prevention program: In Favor of Resilient Self
Study NCT01540773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amino acid supplement
Description: An orally administered supplement of the proprietary amino acid derivative
Study NCT01540773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A non-active orally administered supplement of the proprietary amino acid derivative
Study NCT01989962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E4E intervention
Description: The E4E intervention consists of a one-day face-to-face workshop and a series of follow-up online learning modules. Workshop and online content will be tailored to meet individual participants' needs determined by a pre-program needs assessment. E4E intervention will emphasize clinically based case scenarios and are designed to reinforce the workshop concepts and stimulate reflection. Participating family physicians will attend the workshop and engage in reflections and small-group interactions.
Study NCT01989962 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: E4E intervention
Description: The E4E intervention consists of a one-day face-to-face workshop and a series of follow-up online learning modules. Workshop and online content will be tailored to meet individual participants' needs determined by a pre-program needs assessment. E4E intervention will emphasize clinically based case scenarios and are designed to reinforce the workshop concepts and stimulate reflection. Participating family physicians will attend the workshop and engage in reflections and small-group interactions.
Study NCT04326114 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory training device
Description: Inspiratory training by a Power-breath device
Study NCT04326114 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Expiratory training device
Description: Expiratory training a Winner-flow device
Study NCT03996148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil, Propofol, and Desflurane
Description: Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Propofol - titratable; initial starting dose 75 mcg/kg/min Desflurane 0.5 MAC
Study NCT03996148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil, Dexmedetomidine, and Desflurane
Description: Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Dexmedetomidine - titratable; initial starting dose 0.5 mcg/kg/hr Desflurane 0.5 MAC
Study NCT03996148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil and Desflurane
Description: Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Desflurane - titratable
Study NCT03916510 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enadenotucirev
Description: Enadenotucirev is a live replicating oncolytic adenovirus; it is considered a BioSafety Level 1 (BSL-1) infectious substance.
Study NCT03916510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is a chemotherapy drug licensed for use in rectal cancer, it is a non-cytotoxic pre-cursor of the cytotoxic 5-fluorouracil. Due to Capecitabine not being taken on Enadenotucirev dosing days it is considered an investigational medicinal product within this trial.
Study NCT03916510 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 50 Gy/25#
Study NCT00662519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injections will be given in identical volumes in identical syringes in the identical subcutaneous manner. 6mg/dose given every 2 weeks for 12 weeks. Subjects less than 45kg will receive 100mcg/kg/dose every 2 weeks for 12 weeks.
Study NCT00662519 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed Meal Tolerance Test (MMTT)
Description: This is a 2 hour test to find out how much C-peptide is being produced. C-peptide is used to measure the insulin being made by the cells of the pancreas. Both groups will have this test performed.
Study NCT00662519 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Mixed Meal Tolerance Test (MMTT)
Description: This is a 2 hour test to find out how much C-peptide is being produced. C-peptide is used to measure the insulin being made by the cells of the pancreas. Both groups will have this test performed.
Study NCT00662519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood test
Description: HbA1c is a blood test that measures the average blood sugar control and will be performed in both groups.
Study NCT00662519 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blood test
Description: HbA1c is a blood test that measures the average blood sugar control and will be performed in both groups.
Study NCT00662519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DNA Test
Description: The HLA test looks at the different chromosomes (DNA) for diabetes and will be performed in both groups.
Study NCT00662519 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: DNA Test
Description: The HLA test looks at the different chromosomes (DNA) for diabetes and will be performed in both groups.
Study NCT02327312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stents
Description: Two Trabecular meshwork Micro-Bypass stents into the study eye
Study NCT02327312 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: Laser Trabeculoplasty
Study NCT02327312 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Trabeculoplasty
Study NCT00198367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin-Gemzar
Study NCT00198367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin-Navelbine-Radiotherapy
Study NCT00198367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin-Taxol-Radiotherapy
Study NCT05316818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI Protocol
Description: Triplet chemotherapy regimen consists from active three cytotoxic agents aiming to improve outcomes
Study NCT05316818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOXIRI Protocol
Description: Triplet chemotherapy regimen consists from active three cytotoxic agents aiming to improve outcomes
Study NCT00535444 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parish nurse visit
Description: One visit with the parish nurse in 2 weeks
Study NCT03561246 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Incline treadmill walking
Description: Those with a Pp \<0.47 or >0.53 will undergo INCLINE training during which individuals will walk for 15 minutes at a 10-degree treadmill tilt, stopping each five minutes for monitoring of vital signs.
Study NCT03561246 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decline treadmill walking
Description: Those with a Pp \<0.47 or >0.53 will undergo DECLINE training during which individuals will walk for 15 minutes at a 10-degree treadmill tilt, stopping each five minutes for monitoring of vital signs.
Study NCT03561246 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Level Treadmill (Control)
Description: Those with a Pp \<0.47 or >0.53 will undergo LEVEL training during which individuals will walk for 15 minutes at a 0-degree treadmill tilt, stopping each five minutes for monitoring of vital signs.
Study NCT02820558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Substance P
Study NCT01879189 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breast Cancer Screening Decision Aid
Description: The intervention will include access to the personal decision aid tool for patients in the intervention arm of the study, determined by the randomized physician schedule and the patient's appointment time.
Study NCT02561780 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Curriculum
Description: A mental health educational resource delivered in the classroom by trained educators
Study NCT04295382 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Software Application
Description: A software application targeting suicidal ideation via interactive exercises.
Study NCT02538341 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Herpes Zoster (HZ) Vaccine
Study NCT02538341 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04434742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex interventions
Description: An advanced practice nurse (APN) from a hospital discharge team visited them to familiarize him/herself with their condition and prepare a discharge plan. A face-to-face or telephone call handover between the APN and the project nurse case manager (NCM) was performed before the client was discharged. The past and current medical conditions, medical and nursing management, and follow-up appointments were discussed. After discharge home, the NCM, functioning as the leader of health-social care team, conducted the initial assessment in the first home visit to identify the client's health and social problems within one week of discharge. Community workers, supervised by both the nurse case manager and social worker, provided telephone follow-up and subsequent home visits to monitor the client's progress and provide support when necessary.
Study NCT02561780 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eLearning Follow-up
Description: An online mental health education module that students access individually
Study NCT04434742 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Social call was given to this group.
Study NCT03548857 — intervention group
Intervention type: OTHER
Intervention: Lung transplantation
Description: Single or double lung transplantation in patients with COPD
Study NCT00611559 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix™ penta
Description: Subjects received a booster dose
Study NCT00611559 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix™ hexa
Description: Subjects received a booster dose
Study NCT00611559 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix™ hexa
Description: Subjects received a booster dose
Study NCT04870749 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IPP,IPSS,VPSS
Description: Prostate volume, IPSS, VPSS and IPP were determined after urological examinations of the patients.
Study NCT03874195 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access to PCforMe for review
Description: Intervention Arm subjects will receive access to PCforMe.
Study NCT03874195 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Access to three nationally-recognized Palliative Care websites for review
Description: Subjects in the Active Control arm will receive a list of three nationally-recognized websites to receive information on palliative care
Study NCT04493593 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SilverCloud
Description: 'Space for Sleep' is a seven-module online CBT-based intervention for sleep. The structure and content of the programme modules follow evidence-based CBT principles for insomnia. Each module is structured to incorporate introductory quizzes. videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other users are incorporated into the presentation of the material.~As per normal service provision, each participant will be assigned a clinician (PWP) who will monitor participants' progress through the program. Every one to two weeks, the PWP will login and review participants' progress, leaving feedback for them and responding to the work they have completed.
Study NCT04059874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donafenib tablets
Description: donafenib tablets 100mg qd dose group and donafenib tablets 100mg bid dose group
Study NCT01954836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: initial fasting
Description: modified fasting with daily caloric intake of \<400kcal by juices starting 36 to 48 h before begin of chemotherapy and lasting to 24 h after end of chemotherapy applied in the first half of scheduled 4 or 6 chemotherapy cycles
Study NCT01954836 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Secondary fasting
Description: modified fasting with daily caloric intake of \<400kcal by juices starting 36 to 48 h before begin of chemotherapy and lasting to 24 h after end of chemotherapy applied in the second half of scheduled 4 or 6 chemotherapy cycles
Study NCT01952288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: simvastatin 40 mg/day for 12 months
Study NCT01952288 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo comparator
Study NCT01603212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Phase I Starting dose: 720 mg by mouth twice a day for a 21 day cycle.~Phase II Starting dose: Maximum tolerated dose (MTD) from Phase I.
Study NCT01603212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Phase I Starting Dose: 7 million IU/m2 by vein on Days 2 - 5 of a 21 day cycle.~Phase II Starting Dose: Maximum tolerated dose (MTD) from Phase I.
Study NCT01603212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alpha-2b
Description: 5 million U/m2 subcutaneously on Days 1 - 5 of a 21 day cycle.
Study NCT05941676 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tumour immunoprofile evaluation
Description: Tumour immunoprofile evaluation will be performed in patients with head and neck cancer.
Study NCT04212546 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Synbiotic test drink
Description: In a healthy male population, participants consumed a synbiotic test drink containing 200 mL milk + 16 g inulin + Lactobacillus casei431 \[>106cfu/mL\] per day for 21 days with their habitual diet.
Study NCT04212546 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control drink
Description: In a healthy male population, participants consumed a synbiotic test drink containing 200 mL milk + 16 g maltodextrin per day for 21 days with their habitual diet.
Study NCT03529890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Experimental intervention:~Immunotherapy with 4 cycles of Nivolumab: 240 mg intravenously every 2 weeks, starting one week before radiotherapy (week1, d1), last infusion on week 7, d1
Study NCT03592732 — intervention group
Intervention type: OTHER
Intervention: Blood sample
Description: Blood sample
Study NCT03529890 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy of the pelvis
Description: Neoadjuvant radiation therapy of pelvis with 45+5,4 Gy for 6 weeks: 28 x 1.8 Gy including a boost of bladder with 5.4 Gy, starting with week 2 (d1)
Study NCT03529890 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical cystectomy with standardized pelvic lymphadenectomy
Description: Radical cystectomy with standardized bilateral pelvic lymphadenectomy: performed between week 11 - 15 (Aim: week 13)
Study NCT03185312 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: skin biopsy
Description: Clinical evaluation including full history taking and dermatological examination will be done for all patients. Assessment of disease severity will be performed using VASI score for vitiligo and Global acne severity grading for acne vulgaris Skin biopsies will be taken from lesional and non-lesional skin of patients as well as controls. immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3.~Additionally, biopsies will be preserved in RNA later solution at -20°C. RNA isolation and real-time qPCR analysis will be performed for measurement of cutaneous JAK1, JAK2 and JAK3 gene expression.
Study NCT01570062 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HEPA Filter
Description: Two HEPA filters will be placed in participant's homes (one in the bedroom and one in the main living area); each HEPA will run for 2 consecutive 7-day sampling sessions. During one of the 7-day sampling sessions, the HEPA filter will run without the internal filter in place (i.e., placebo filtration).
Study NCT01570062 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: HEPA Filtration Placebo
Description: for one of the two 7-day sampling sessions, both HEPA filters placed in participants' homes will be run without the actual filter in the housing unit.
Study NCT02394223 — intervention group
Intervention type: PROCEDURE
Intervention: Full Field Optical Coherence Tomography (FFOCT) procedure
Description: TRUS Prostate biopsy are performed under the care procedure Pathological examination of these prostate biopsy with FFOCT procedure, as compared to standard pathological evaluation
Study NCT04261881 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ATP-Fuel
Description: 5 capsules daily with breakfast and 5 capsules daily with lunch
Study NCT04261881 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ATP-II
Description: 3 capsules daily with breakfast
Study NCT04261881 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ATP-II
Description: 3 capsules daily with breakfast and 3 capsules daily with lunch
Study NCT03274245 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Package
Description: * Community Level:~  * Palla: songs and skits to increase knowledge of and motivation for latrine use, pit emptying, safe feces disposal;~ * Transect Walk: village walk to identify and mark feces in community;~ * Community meetings: sex-segregated meetings with village members to decide on an action plan to increase community cleanliness/reduce open defecation;~ * Wall painting: village map noting households that use latrines always.~* Sub-Community level:~  * Mothers meeting: For caregivers with children under age 5, to provide knowledge of and hardware for safe child feces disposal.~* Household Level:~  * Household visits: to those with latrines to motivate use;~ * Latrine repairs: for households with non-functional latrines to make functional.
Study NCT03274245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qualitative Research
Description: For villages receiving the intervention package, investigators will engage community members through qualitative interviews to gain their perception of the intervention, what they thought of the intervention activities, what information they recall, what aspects they enjoyed or disliked, if they had barriers to attendance or participation.~For the three villages not receiving the intervention, investigators will conduct qualitative interviews to determine additional barriers and determinants of latrine use to identify other potential intervention strategies.
Study NCT02150512 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transpulmonary Thermodilution
Description: Initial trigger for fluid loading when circulatory insufficiency is present will be SVV. If SVV ≤10% in patients on controlled mechanical ventilation with tidal volumes of ≥8 ml/kg, fluid loading will not be performed. If SVV >10% or spontaneous breathing efforts are present, a fluid challenge should be performed. Also if patients are on controlled mechanical ventilation with tidal volumes of ≤7 ml/kg, a fluid challenge should be performed. If fluid responsiveness is present and SVV decreases to ≤10%, further fluid loading should be stopped. If SVV is still >10%, the increase in EVLW will decide whether to continue fluid loading or not; if EVLW is ≥12 mL/kg PBW and EVLW increases upon fluid loading, further fluid loading should be stopped.
Study NCT02150512 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surviving Sepsis Guidelines (SSG)
Description: Initial trigger for fluid loading when circulatory insufficiency is present will be the CVP (target ≥12 mmHg). If circulatory insufficiency is absent, fluid loading will not be initiated or stopped independently of the actual CVP level.
Study NCT01856803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti thymoglobulin
Study NCT01856803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti thymoglobulin
Study NCT00588757 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optease IVC filters
Description: IVC filters will be implemented and evaluated for retrieval after 2-3 weeks.
Study NCT00588757 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gunter-Tulip IVC filters
Description: IVC filters will be implemented and evaluated for retrieval after 2-3 weeks.
Study NCT04864600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Candle C
Description: Burning candles will produce particulate air pollution being passed on an exposure chamber where the participants will be sitting for 5 hours.
Study NCT04864600 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Candle 1
Description: Burning candles will produce particulate air pollution being passed on an exposure chamber where the participants will be sitting for 5 hours.